ArticlePulmonary therapy2026
Healthcare Resource Utilization and Medical Costs in Pulmonary Arterial Hypertension Management in Japan: A Retrospective Study Using a Claims Database.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate the healthcare resource utilization (HCRU), medical costs in pulmonary arterial hypertension (PAH) patients in Japan, implementation of right heart catheterization (RHC), and treatment intensity, a retrospective observational cohort study using a nationwide health insurance claims database provided by JMDC Inc. was conducted.
methodsPatients with PAH, classified based on evidence of a PAH diagnosis and PAH-targeted drug prescription within the same calendar month, were identified from the database. Demographic and clinical characteristics, as well as the implementation of RHC during the baseline period and the type of PAH-targeted drugs prescribed for the first-line therapy, were described. Outcomes included HCRU and direct medical costs between March 1, 2018 and March 31, 2023.
resultsA total of 405 patients with PAH were included in the analyses; 298 patients (73.6%) did not undergo RHC [RHC(-) cohort], and 107 patients (26.4%) underwent RHC [RHC(+) cohort] during the baseline period. Among the overall population, 59.3% received oral/inhaled monotherapy and 5.4% received parenteral prostacyclin analogue (PPA) combination therapy; 70.1% of the RHC(-) cohort received oral/inhaled monotherapy versus 29.0% in the RHC(+) cohort, 1.7% of the RHC(-) cohort received PPA combination therapy versus 15.9% in the RHC(+) cohort. Overall, the HCRU and the total medical costs tended to increase with treatment intensity in both RHC(-) and RHC(+) cohorts. The increase of the medical costs was mainly due to increase in costs related to hospitalization and prescription of PAH-targeted drugs.
conclusionThe results revealed that HCRU and medical costs were especially high in those who were treated intensively with PPA combination therapy at first-line. In terms of extensive HCRU and associated medical costs, the limitations of existing treatment strategies for PAH were noted. In addition, these results highlight the need for innovative treatments to reduce the considerable disease burden described in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.